Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fes, Morocco.
Moahammed VI Center for Cancer Care, Casablanca, Morocco.
J Cancer Policy. 2023 Sep;37:100428. doi: 10.1016/j.jcpo.2023.100428. Epub 2023 Jun 22.
Lung cancer is the most common cancer in men and the second most common cancer in women. It is associated with substantial economic impact in terms of direct and indirect costs. The main objective of this study is to estimate the direct medical cost of lung cancer management in Morocco MATERIALS AND METHODS: A cost-of-illness study was conducted among patients treated at the Mohammed VI Center of Cancer (Casablanca) in 2019. The costs were estimated from the societal perspective using a bottom-up approach. The materials and procedures used were identified and quantified retrospectively from the information system and files. Their monetary value was calculated according to official prices published by the national health insurance agency. The horizon time adopted was 12 months.
The study included 271 patients, with an average age of 62.5 ± 9.5 years. Of these, 93.4 % were men and 92.1 % were former smokers. In terms of cancer staging, 68.3 % of patients were in stage IV while 28.8 % were in stage III. Adenocarcinoma was present in 43.5 % of cases. Patients underwent an average of 10.6 ± 5.1 radiological investigations, 56.1 ± 30.9 biological tests, and 24.1 ± 11.7 consultations. The average direct medical cost was 4455.3 USD (95 % CI: 4037.4-4873.2). Chemotherapy accounted for 19.9 % of the total cost, while radiological investigations and drugs accounted for 18.7 % and 17.6 %, respectively. Diagnostic tests and radiotherapy each accounted for 7.6 % of the total cost, while biological tests accounted for 7.5 % and hospitalizations accounted for 7.1 %. The cost was statistically higher in young patients (p = 0.017), in patients with adenocarcinoma (p < 0.0001), in patients with stage II tumor (< 0.00001), in patients who have undergone surgery (p = 0.002), chemotherapy (p < 0.0001), radiotherapy (p < 0.001) and in those without metastases (p < 0.0001).
These results provide evidence to support the ratification of the Framework Convention on Tobacco Control and the full adherence of the Kingdom of Morocco to the MPOWER measures.
肺癌是男性中最常见的癌症,也是女性中第二常见的癌症。它在直接和间接成本方面带来了巨大的经济影响。本研究的主要目的是估计摩洛哥肺癌管理的直接医疗成本。
在 2019 年,对在穆罕默德六世癌症中心(卡萨布兰卡)接受治疗的患者进行了一项疾病成本研究。使用自下而上的方法,从社会角度估算了成本。使用信息系统和文件,回顾性地确定和量化了材料和程序,并根据国家健康保险机构公布的官方价格计算了其货币价值。采用的时间范围为 12 个月。
研究共纳入 271 名患者,平均年龄为 62.5 ± 9.5 岁。其中,93.4%为男性,92.1%为前吸烟者。就癌症分期而言,68.3%的患者处于 IV 期,28.8%的患者处于 III 期。腺癌占 43.5%。患者平均接受了 10.6 ± 5.1 次影像学检查、56.1 ± 30.9 次生物学检查和 24.1 ± 11.7 次就诊。直接医疗费用平均为 4455.3 美元(95%置信区间:4037.4-4873.2)。化疗占总成本的 19.9%,影像学检查和药物分别占 18.7%和 17.6%。诊断性检查和放射治疗各占总成本的 7.6%,生物学检查占 7.5%,住院治疗占 7.1%。在年轻患者(p=0.017)、腺癌患者(p<0.0001)、肿瘤 II 期患者(<0.00001)、接受手术治疗的患者(p=0.002)、接受化疗的患者(p<0.0001)、接受放射治疗的患者(p<0.001)和无转移患者(p<0.0001)中,成本较高。
这些结果为支持摩洛哥批准《烟草控制框架公约》和王国全面遵守《MPOWER 措施》提供了证据。